---
title: "MBX Biosciences, Inc. (MBX) Gets a Buy from Mizuho Securities"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295281238.md"
description: "Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences (MBX) with a $91 price target. Barclays also maintained a Buy rating with an $88 target. Ear, a 4-star analyst in the Healthcare sector, has a 7.8% average return and 44.59% success rate."
datetime: "2026-08-07T20:55:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295281238.md)
  - [en](https://longbridge.com/en/news/295281238.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295281238.md)
generator: "portal-rs"
---

# MBX Biosciences, Inc. (MBX) Gets a Buy from Mizuho Securities

Mizuho Securities analyst Uy Ear reiterated a Buy rating on MBX Biosciences, Inc. today and set a price target of $91.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Ear is a 4-star analyst with an average return of 7.8% and a 44.59% success rate. Ear covers the Healthcare sector, focusing on stocks such as Alkermes, Evolus, and Arcutis Biotherapeutics.

In a report released today, Barclays also maintained a Buy rating on the stock with a $88.00 price target.

### Related Stocks

- [MBX.US](https://longbridge.com/en/quote/MBX.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)
- [EOLS.US](https://longbridge.com/en/quote/EOLS.US.md)
- [ARQT.US](https://longbridge.com/en/quote/ARQT.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)

## Related News & Research

- [Analyst Maintains Buy on Microbix as China Antigen Sales Normalize and Revenue Growth Recovers](https://longbridge.com/en/news/296018935.md)
- [MBX Biosciences, Inc. (NASDAQ:MBX) Receives Average Rating of "Moderate Buy" from Analysts](https://longbridge.com/en/news/294163609.md)
- [Roth MKM Sticks to Their Buy Rating for Courtside Group Inc (PODC)](https://longbridge.com/en/news/296226112.md)
- [Analyst Reaffirms Buy on Life Time Group as Strong Results and 15–16% EBITDA CAGR Outlook Justify Higher Valuation Multiples](https://longbridge.com/en/news/296219793.md)
- [US families, healthcare providers under strain after Trump crackdown on Haitian immigrants](https://longbridge.com/en/news/296335867.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**